...
首页> 外文期刊>Urologia internationalis >Clinical Outcome of Patients with Lymph Node-Positive Prostate Cancer following Radical Prostatectomy and Extended Sentinel Lymph Node Dissection
【24h】

Clinical Outcome of Patients with Lymph Node-Positive Prostate Cancer following Radical Prostatectomy and Extended Sentinel Lymph Node Dissection

机译:根治性前列腺切除术和前哨大淋巴结清扫术后淋巴结阳性前列腺癌患者的临床结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: This study sought to evaluate the clinical outcome after extended sentinel lymph node dissection (eSLND) and radical retropubic prostatectomy (RRP) in patients with clinically localized prostate cancer (PCa). Subjects and Methods: From August 2002 until February 2011, a total of 819 patients with clinically localized PCa, confirmed by biopsy, were treated with RRP plus eSLND. Biochemical recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were assessed with Kaplan-Meier curves. Various histopathological parameters were analyzed by univariate and multivariate analysis. Results: The mean follow-up was 5.3 years. Lymph node (LN) metastases occurred in 140 patients. We removed an average of 10.9 LNs via eSLND from patients with pN1 PCa. Postoperatively, 121 pN1 patients temporarily received adjuvant androgen deprivation therapy. The mean survival periods for RFS, RFS after secondary treatment, CSS, and OS were 4.7, 7.0, 8.8, and 8.1 years, respectively. The cancer-specific death rate of the 140 pN1 patients was 13.6%. RFS, CSS, and OS were significantly correlated with pathological margin status, LN density, the total diameter of evident metastases, and membership in the subgroup 'micrometastases only'. Conclusion: Despite the presence of LN metastases, patients with a low nodal tumor burden demonstrate a remarkable clinical outcome after undergoing eSLND and RRP, thus suggesting a potential curative therapeutic approach. (C) 2014 S. Karger AG, Basel
机译:目的:本研究旨在评估临床上局限性前列腺癌(PCa)患者的前哨淋巴结清扫术(eSLND)和根治性耻骨后前列腺切除术(RRP)后的临床疗效。对象和方法:从2002年8月至2011年2月,经活检证实的总共819例临床定位的PCa患者接受RRP加eSLND治疗。使用Kaplan-Meier曲线评估了无生化复发生存期(RFS),癌症特异性生存期(CSS)和总生存期(OS)。通过单因素和多因素分析来分析各种组织病理学参数。结果:平均随访时间为5.3年。 140例患者发生了淋巴结转移。我们通过eSLND从患有pN1 PCa的患者中平均移除了10.9个LN。术后,有121名pN1患者暂时接受了辅助性雄激素剥夺治疗。 RFS,二次治疗后RFS,CSS和OS的平均生存期分别为4.7、7.0、8.8和8.1年。 140名pN1患者的癌症特异性死亡率为13.6%。 RFS,CSS和OS与病理边缘状态,LN密度,明显转移的总直径和“仅微转移”亚组的成员显着相关。结论:尽管存在LN转移,但结节肿瘤负荷低的患者在接受eSLND和RRP后仍表现出显着的临床结局,从而提示了一种潜在的治疗方法。 (C)2014 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号